• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Ask the Expert / Remicade cross placental barrier during pregnancy?

Remicade cross placental barrier during pregnancy?

April 3, 2007 By Arthritis Center

Question

I read your response to the Humera/pregnancy question in March and found it informative. Thank you for posting it. At age 29, My RA and CD had rendered me mostly bed-ridden and constantly in and out of hospitals for about four years. Two years ago, Remicade “gave me my life back”. Prior to that, my husband and I had given up on the idea of ever starting a family. Today, my husband and I are excited to announce that we are pregnant! Our embryo is on its 22nd day post conception (using a healthy egg donor). Everything is going even better than expected! Delivery predicted around May 1, 2007. My last Remicade infussion was one week prior to IVF (4 vials/6 wks), and my last Methotexate injection was five months ago. I stopped my Celebrex three days prior to implantation. Surprisingly, I am doing very well, no complaints that Tylenol can’t take care of. I am hoping that I am one of the 80% of women who experience remission as a result of pregnancy. However, it would be a tremendous relief to me (prior to having to make the decision to use Remicade to finish out the pregnancy only if severe symptoms re-occur), TO BE AWARE OF ANY REPORTED SIDE-EFFECTS ON EMBRYONIC/FETAL DEVELOPMENT AND THE USE OF REMICADE (human or animal studies). My Rheumatologist reported to me that in fetal mice studies, Remicade did not pass the placental barrier. Have you heard any such results? Finally, I know you are a very busy professional; however, I personally applaud you for opening your heart to those of us who are in desperate need of specific information which we find close to impossible to locate.

Answer

There has been no studies to date that show an increase in birth defects with the TNF agents, but the studies are small. Thus we continue to stop the TNF agents during preganancy. I am not aware of the study your rheumatologist is referencing, but to my knowledge Remicade like all antibodies cross the placental barrier. Congratulations on your pregnancy!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Primary Sidebar

Ask The Expert Topics

  • Alternative Therapies
  • Ankylosing Spondylitis
  • Associated With Other Illnesses
  • Bursitis and Tendinitis
  • Corticosteroids
  • Diet and Exercise
  • Disease Modifying Antirheumatic Drugs (DMARDs)
  • Enteropathic Arthritis
  • Fibromyalgia
  • General Arthritis
  • Gout, Pseudogout, Other
  • Infectious Arthritis
  • Myositis
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Osteoarthritis
  • Osteonecrosis
  • Osteoporosis
  • Polymyalgia Rheumatica
  • Psoriatic Arthritis
  • Reactive Arthritis
  • Regional Pain: Back and Neck
  • Rehabilitation
  • Rheumatoid Arthritis
  • Surgical Therapy
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis
  • Vasculitis
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy